Skip to main content
. 2015 Oct 5;10(10):e0137305. doi: 10.1371/journal.pone.0137305

Fig 9. Effect of IDT effect on Aβ.

Fig 9

Following 38 weeks of IDT treatment, analysis of 6E10 (APP/Aβ) or Aβ42 immunolabeling in the hippocampus of 16 month-old 3xTgAD mice was performed on 50 μm sections, every 12th section through the hippocampus, by densitometry and % area covered by immunostaining. (A) Representative pictures of 6E10 staining in each treatment group (10x magnification; Bar equals 50 μm) with corresponding % Area and densitometry. Similarly, Aβ42 immunolabeling and quantification is shown in (B). Elimination of the primary antibody from the staining protocol resulted in loss of specific staining (data not shown). Data represent mean ± SEM of n = 8–10/group. (C) Results from soluble and insoluble hippocampal fractions analyzed by Aβ40 or 42-specific ELISA. One-way ANOVA did not reveal an overall significant effect of IDT treatment on either soluble Aβ40 (p = 0.0604) or Aβ42 (p = 0.1181). High dose IDT did significantly reduce soluble Aβ40 versus Con (*p < 0.05). There was an overall significant effect of IDT dose on insoluble Aβ40 levels (p = 0.0135) but insoluble Aβ42 did not quite reach significance (p = 0.0649). Both Low and High dose IDT reduced insoluble Aβ40 versus Con (*p< 0.05 and **p< 0.01). High dose IDT reduced insoluble Aβ42 (*p<0.05).